The Seventh Affiliated Hospital of Sun Yat-sen University
33
3
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.0%
1 terminated/withdrawn out of 33 trials
88.9%
+2.4% vs industry average
18%
6 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (33)
A Feasibility Study of Death Education Intervention for Family Caregivers of Advanced Cancer Patients
Role: collaborator
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
Role: collaborator
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Role: collaborator
Efficacy of Two Approaches in Cervical Single-door Laminoplasty for Spinal Canal Enlargement
Role: collaborator
Chinese Osteoporotic Fracture Registration Network Platform
Role: collaborator
Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Role: collaborator
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
Role: collaborator
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
Role: collaborator
Research on Key Technology Development and Clinical Application of Small Interactive Spinal Endoscopic Surgery Robot
Role: collaborator
Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes
Role: collaborator
Time-Restricted Feeding on Cardiovascular Health Effects
Role: collaborator
Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures
Role: lead
Differentiating Between Brain Hemorrhage and Contrast
Role: collaborator
Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection
Role: lead
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
Role: collaborator
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
Role: collaborator
VAH Versus VA for Salvage Therapy of R/R-AML
Role: collaborator
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
Role: collaborator
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
Role: collaborator
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Role: collaborator